Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.
Mercieca-Bebber R, Barnes EH, Wilson K, Samoon Z, Walpole E, Mai T, Ackland S, Burge M, Dickie G, Watson D, Leung J, Wang T, Bohmer R, Cameron D, Simes J, Gebski V, Smithers M, Thomas J, Zalcberg J, Barbour AP.
Mercieca-Bebber R, et al. Among authors: thomas j.
BMC Cancer. 2022 Mar 15;22(1):276. doi: 10.1186/s12885-022-09270-4.
BMC Cancer. 2022.
PMID: 35291965
Free PMC article.
Clinical Trial.